zentalis pharmaceuti

Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types.Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib.Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes.Our mission: to unburden cancer patients with more convenience and care.